The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found.

GlaxoSmithKline’s deal to buy Pfizer’s consumer healthcare business will not lesson competition in Australia, the country’s anti-trust regulator said.

Australia’s competition watchdog said the High Court dismissed its special leave application to appeal a court’s decision on whether Pfizer Inc.’s local unit used the company’s market power to limit competition for the cholesterol-lowering drug Lipitor.

An Australian court dismissed an appeal by the nation’s anti-trust watchdog in a case against Pfizer Inc. in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor.